SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai ($BBAI) is trending amid discussions about its acquisition of Ask Sage, an AI platform, and anticipation for the earnings call. The community is focused on the potential revenue from Ask Sage and its role in AI defense, with some hoping for significant stock movement soon. Recent after-hours momentum and AI sector strength may also be contributing to the increased attention.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending due to an after-hours tumble following its earnings report, despite a revenue beat; the company's lowered guidance is the primary concern, overshadowing positive metrics such as backlog growth. Community discussion revolves around whether this drop presents a buying opportunity or signals deeper issues, particularly related to revenue recognition and data center delays. Some traders believe the dip is an overreaction and a temporary setback for this AI infrastructure play.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as chatter increases around potential adoption by governments and its role in providing data to platforms like Kalshi. Community members are speculating on the potential impact of real-world asset (RWA) integration and comparing it to other cryptocurrencies.

Biggie is a popular Pitbull across several social media platforms, such as Tiktok, Youtube and Instagram. With a blend of creativity and comedic gestures, Biggie brings animal loving entertainment to millions of viewers through images, videos and reels. With Biggie the Pitbull's growing popularity, the meme coin $BIGGIE was inspired and launched on the ethereum network, leveraging Biggies unique sense of humor and style.

Biggie

Bigg has captured the attention of the crypto community, with many highlighting the influx of new traders and its trending status. Fueling the excitement are comparisons to other meme coins like Shiba Inu and Doge, with some suggesting BIGGIE has the potential for significant growth. Community members are encouraging each other to load up, emphasizing the potential for substantial returns.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as the community discusses the potential impact of a new CEO pay package and the upcoming R2 model launch. Bullish sentiment seems to be fueled by strong volume and the anticipation of Rivian's AI and Autonomy Day in December. Some investors are drawing parallels to Tesla's growth trajectory, while others remain cautious, citing profitability concerns.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap ($UNI) is trending as traders discuss its potential for significant gains and its strong technical setup. The community is actively watching for breakout opportunities and anticipating a potential surge, drawing comparisons to previous altcoin season patterns. Some users are pointing to the protocol's strong fundamentals, including substantial fee generation, as a reason for optimism.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as investors discuss its recent delivery numbers and potential path to profitability, while also comparing its performance and strategy to competitors like Xpeng and Tesla. Community talking points include concerns about stock dilution and the effectiveness of NIO's battery swapping technology. The stock's movement relative to peers and the broader market seems to be fueling frustration and debate among investors.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

Galecto Inc. ($GLTO) is trending due to its acquisition of Damora Therapeutics and a substantial funding round, leading to a massive surge in price and volume. Community discussions revolve around the potential for a multi-day run and a possible short squeeze, with some cautioning about potential pullbacks. The stock's low float and recent news are key factors driving the intense interest and volatility.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in New York, NY.

Bakkt Holdings Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

BKKT is trending due to recent price volatility and community discussions around earnings expectations, potential partnerships, and the impact of crypto market movements. Traders are actively discussing options strategies and the company's future prospects, with some expressing concerns about dilution and past performance. The addition of new board members and their potential influence is also a key talking point.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending amid anticipation for the CHMP opinion on its Alzheimer's drug, Blarcamesine, with a decision potentially arriving soon. Community discussions revolve around the likelihood of approval, the potential for a short squeeze, and speculation on future partnerships. Some believe approval is imminent due to the drug's safety profile and convenience compared to existing treatments, while others remain cautious, awaiting the official announcement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Momentum Stock to Buy for October 10th

SPRO made it to the Zacks Rank #1 (Strong Buy) momentum stock list on October 10, 2025.

Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease 

BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.

Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround 

The heavy selling pressure might have exhausted for Spero Therapeutics (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease

BAYRY begins human trials for OpCT-001, an experimental cell therapy for treating primary photoreceptor diseases.

AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer

AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.

Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.

RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance

FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.

ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B

AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.

Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Spero Therapeutics Inc

$NVDA

$MSFT

$AAPL

$GOOGL

Which of these Mag 7 stocks are you most bullish on right now?

SPRO
Spero Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SPRO News

SPROSpero Therapeutics Inc